Do You Have These Pharma Stocks In Your Portfolio? (EARS, BLRX, OMED…)

Do You Have These Pharma Stocks In Your Portfolio? (EARS, BLRX, OMED…)
Clinical trials are major catalysts for biotech/pharma companies as positive study data can boost the stock price while unfavorable results can send the stocks plummeting. The success rate of phase I clinical programs is the highest, say 63%, while it is the lowest for phase II trials – i.e. 30%. The phase III trials, which are the longest and most... Read More

SNGX Flashes DMC Recommendation, LENS On Watch, IOVA Slumps

SNGX Flashes DMC Recommendation, LENS On Watch, IOVA Slumps
The following are some of the pharma/biotech stocks that posted the biggest percentage decline today. 1. Soligenix Inc. (SNGX) Lost 26.21% to close Monday’s (Oct.15) trading at $1.07. News: An independent Data Monitoring Committee has recommended that approximately 40 additional subjects be randomized into the Company’s phase III study for SGX301 in the treatment of cutaneous T-cell lymphoma, dubbed FLASH.... Read More

Krystal Bio Shines, CGC Hits Lifetime High, ANIX On Watch, CRON Gathers Steam

Krystal Bio Shines, CGC Hits Lifetime High, ANIX On Watch, CRON Gathers Steam
The following are some of today’s top gainers in the pharma/biotech sector. 1. Krystal Biotech Inc. (KRYS) Gained 27.55% to close Monday’s (Oct.15) trading at $20.00. News: The Company announced positive interim results from its ongoing placebo-controlled phase I/II clinical trial of KB103 to treat dystrophic epidermolysis bullosa, or DEB. DEB is an incurable, often fatal skin blistering condition caused... Read More

EyePoint Pharma shares jump on FDA approval of Yutiq implant

EyePoint Pharma shares jump on FDA approval of Yutiq implant
EyePoint Pharmaceuticals Inc. shares EYPT, +5.56% soared 8% in premarket trade Monday, after the company said the U.S. Food and Drug Administration has approved its Yutiq implant for the treatment of uveitis, a leading cause of blindness. Yutiq is a micro-insert that is designed to release fluocinolone acetonide over a three-year period and that can be administered in a doctor’s... Read More

Asian Shares Extend Slide As Trade Fears Persist

Asian Shares Extend Slide As Trade Fears Persist
Asian stocks fell on Monday to extend last week’s slide as worries about global trade and higher U.S. interest rates lingered. A growing feud between the U.S. and Saudi Arabia over the disappearance of a prominent Saudi journalist also weighed on investors’ risk appetite. Chinese shares tumbled to extend last week’s rout as traders remained on edge ahead of European... Read More

AFMD Bleeds On Clinical Hold, BHC Gets FDA Nod, MNLO Disappoints

AFMD Bleeds On Clinical Hold, BHC Gets FDA Nod, MNLO Disappoints
Today’s Daily Dose brings you news about clinical hold on Affimed’s AFM11 phase I program; Altimmune’s $25 million registered direct offering; FDA approval of Bausch Health’s BRYHALI Lotion; Menlo’s disappointing phase II trial results of Serlopitant and Recro Pharma’s anticipated make or break event. Read on… Shares of Affimed N.V. (AFMD) plunged 25% in extended trading on Monday, following the... Read More

Week Ahead In Pharmaceuticals: 6 Stocks To Watch (BPMC, BHC, ACRX…)

Week Ahead In Pharmaceuticals: 6 Stocks To Watch (BPMC, BHC, ACRX…)
Another week has rolled by, and the biotech sector, being a volatile one, saw some stocks soaring to the moon and some hitting the skids. vTv Therapeutics Inc. (VTVT) closed the week, up 238%, at $3.35. The Company’s most advanced drug candidate is Azeliragon, which failed in a phase III trial in patients with mild Alzheimer’s disease, dubbed STEADFAST. Vaxart... Read More

UPDATE: Arrowhead Pharma stock surges 19% on news of $3.7 billion license agreement with Janssen

UPDATE: Arrowhead Pharma stock surges 19% on news of $3.7 billion license agreement with Janssen
Arrowhead Pharmaceutics Inc. stock ARWR, -5.79% surged 19% in premarket trade Thursday, after the company said it has entered a $3.7 billion license and cooperation agreement with Janssen Pharmaceuticals Inc. to develop and commercialize its ARO-HBV treatment for chronic hepatitis B. As part of the deal, Arrowhead will receive $175 million upon close and Janssen parent Johnson & Johnson Innovation... Read More

Arrowhead Pharma enters $3.7 billion license and cooperation agreement with Janssen

Arrowhead Pharma enters $3.7 billion license and cooperation agreement with Janssen
Arrowhead Pharmaceutics Inc. ARWR, -5.79% said Thursday it has entered a $3.7 billion license and cooperation agreement with Janssen Pharmaceuticals Inc. to develop and commercialize its ARO-HBV treatment for chronic hepatitis B. As part of the deal, Arrowhead will receive $175 million upon close and Janssen parent Johnson & Johnson Innovation JJDC Inc., a unit of Johnson & Johnson JNJ,... Read More